The week in pharma: action, reaction and insight – week to April 12, 2024
By Barbara Obstoj-Cardwell. Editor
Among last week’s regulatory news, the US Food and Drug Administration (FDA) approved an additional indication for pharma major Bristol Myers Squibb and 2seventy bio’s Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy. The US Justice Department filed a False Claims Act complaint against Regeneron regarding the pricing of its eye diseases drug Eylea. On the M&A front, Vertex Pharma last Wednesday announced that it is acquiring fellow USA-based Alpine Immune Sciences and its kidney disease candidate povetacicept for $4.6 billion. Also of note, Arvinas last week entered into a potential $1 billion plus licensing deal with Swiss pharma giant Novartis for its prostate cancer candidate ARV-766.
FDA approval for Abecma in 3L+ r / r MM
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze